Evidence map›Paper›PMID 42620371›Full record

ArticleResearch square2026

A dual pronged approach to cancer immune exclusion: tumor-derived LAIR-1 simultaneously drives fibrosis and blocks immune recruitment in glioma.

Maria Luisa Varela, Henry Kast, Molly West, Marisa Rose, Daiana Perez Visñuk, Mary Violet Springer, Sadhakshi Raghuram, Ziwen Zhu, Yichen Wang, Brandon McClellan and 8 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Maria Luisa VarelaDepartment of Neurosurgery, University of Michigan Medical School; Ann Arbor, MI 48109, USA.
Henry KastDepartment of Neurosurgery, University of Michigan Medical School; Ann Arbor, MI 48109, USA.ORCID 0009-0005-1353-3193
Molly WestDepartment of Neurosurgery, University of Michigan Medical School; Ann Arbor, MI 48109, USA.ORCID 0000-0002-9587-5760
Marisa RoseDepartment of Neurosurgery, University of Michigan Medical School; Ann Arbor, MI 48109, USA.
Daiana Perez VisñukDepartment of Neurosurgery, University of Michigan Medical School; Ann Arbor, MI 48109, USA.
Mary Violet SpringerDepartment of Neurosurgery, University of Michigan Medical School; Ann Arbor, MI 48109, USA.
Sadhakshi RaghuramDepartment of Neurosurgery, University of Michigan Medical School; Ann Arbor, MI 48109, USA.
Ziwen ZhuDepartment of Neurosurgery, University of Michigan Medical School; Ann Arbor, MI 48109, USA.ORCID 0000-0002-6681-9153
Yichen WangDepartment of Computational Medicine and Bioinformatics, University of Michigan; Ann Arbor, MI 48109, USA.
Brandon McClellanDepartment of Neurosurgery, University of Michigan Medical School; Ann Arbor, MI 48109, USA.
Andrea CombaDepartment of Neurosurgery, University of Michigan Medical School; Ann Arbor, MI 48109, USA.
Bhuvna MurthyDepartment of Neurosurgery, University of Michigan Medical School; Ann Arbor, MI 48109, USA.
Fateme Karimi HafshejaniDepartment of Neurosurgery, University of Michigan Medical School; Ann Arbor, MI 48109, USA.
Hend AlMunaidiDepartment of Neurosurgery, University of Michigan Medical School; Ann Arbor, MI 48109, USA.
Marta EdwardsDepartment of Neurosurgery, University of Michigan Medical School; Ann Arbor, MI 48109, USA.
Joshua WelshDepartment of Computational Medicine and Bioinformatics, University of Michigan; Ann Arbor, MI 48109, USA.ORCID 0000-0002-5869-2391
Maria G CastroDepartment of Neurosurgery, University of Michigan Medical School; Ann Arbor, MI 48109, USA.
Pedro R LowensteinDepartment of Neurosurgery, University of Michigan Medical School; Ann Arbor, MI 48109, USA.ORCID 0000-0002-8427-4409

Funding

XenograftP30CA046592 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Eric R. Fearon · 1988 to 2026
$178.2M
Immune-suppressive Myeloid Cells in the Glioma Microenvironment: Signaling Mechanisms and Novel Therapeutic StrategiesR37NS094804 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CASTRO, MARIA G · 2015 to 2021
$2.9M
Systemic Delivery of Targeted Bi-Compartmental Nanoparticles for Glioblastoma Therapeutics (Supplement)R01NS124167 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Maria G Castro, JOERG LAHANN · 2022 to 2026
$2.6M
Uncover the role of H3.3-G343R mutation in shaping the DNA damage response, anti-tumor immunity and mechanisms of resistance in glioma.R01NS122165 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Maria G Castro · 2022 to 2026
$2.5M
The Role of Collagen and its Signaling Mechanisms in Glioma Progression and Invasion.R01NS122234 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Pedro R. Lowenstein · 2022 to 2026
$2.4M
Chemo-immunotherapy strategy for pediatric high grade gliomaR21NS123879 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CASTRO, MARIA G, SCHWENDEMAN, ANNA · 2021 to 2021
$429k
NCI NIH HHS P30 CA046592NINDS NIH HHS R01 NS122165NINDS NIH HHS R01 NS122234NINDS NIH HHS R01 NS124167NINDS NIH HHS R21 NS123879NINDS NIH HHS R37 NS094804
6 · The paper itself

Abstract

Glioblastoma is among the most lethal human malignancies. Immune-based therapies have failed due to a strong immunosuppressive tumor microenvironment (TME)

Identifiers

PMID42620371
PMCPMC13484828

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.